Articles

Results 1 to 5 of 20


Commercialising therapeutic drugs in China: cross-border contract manufacture in doubt

China - August 3 2022 Since the introduction of a nationwide Marketing Authorization Holder (MAH) system in 2019, licenses have linked directly to therapeutic products…

Yang Fan, Lingbi Li

China’s healthcare industry is booming. What investment opportunities does it bring?

China - August 3 2022 The health sector in China is experiencing unprecedented growth. A variety of factors, including extended life expectancy, an Aging population and…

Jessica Horn, Edwina Kwan, Suzy Madar

如何理解“第三方平台提供者不得直接参与药品网络销售活动”

Asia-Pacific, China - June 27 2022 日前,在《药品管理法实施条例(修订草案征求意见稿)》(“征求意见稿”)发布一个多月以后,“国家拟禁第三方平台直接参与药品网售”的消息突然引发关注冲上热搜,并一度导致相关公司股价大跌。有媒体称该规定将对医药电商第三方平台公司的业务造成较大影响。针对这一说法,本文拟就该规定对医药电商第三方平台(“第三…

Huang Zhongbin

Cross-Border CMO Structure Still in Doubt under China MAH Rules

China - June 23 2022 Since the introduction of a nationwide Marketing Authorization Holder (MAH) system in 2019, licenses have linked directly to therapeutic products…

Yang Fan, Li Lingbi

China relaxes rules on lab-developed tests - but uncertainties remain

China - May 19 2022 New regulations in China designed to encourage innovation in clinical trials have made it easier to test human samples in a lab setting. Lab tests on…

Yang Fan